Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

Exclusion Criteria

• •1. Self-reported Caucasian or White race
• •2. Adolescent body weight less than 30 kg at screening
• •3. Prior use of dupilumab within 6 months of screening
• •4. Concomitant skin diseases or other pigmentary disorder that could confound AD assessments
• •5. Current or prior use, within 12 weeks before the screening visit, of phototherapy or tanning beds
• •6. Active helminthic infections; suspected or high risk of helminthic infection, unless clinical and (if necessary) laboratory assessments have ruled out active infection before baseline
• •7. Treatment with topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) within 7 days prior to baseline
• •8. Planned or anticipated use of any prohibited medications and procedures, as defined in protocol
• •9. Has received a COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study drug